Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-03
DOI
10.1038/s41598-018-30158-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
- (2016) Xiaoxin Wu et al. Anti-Cancer Agents in Medicinal Chemistry
- Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay
- (2016) Elodie Jouan et al. Pharmaceutics
- Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy
- (2015) Anna Barbuti et al. Cancers
- Targeting Microtubules by Natural Agents for Cancer Therapy
- (2014) E. Mukhtar et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
- (2012) Tongyuan Li et al. CELL
- Impairment of the Ubiquitin-Proteasome Pathway by MethylN-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells
- (2012) Nilambra Dogra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
- (2012) Yan Lu et al. PHARMACEUTICAL RESEARCH
- Metabolic regulation by p53
- (2011) Oliver D. K. Maddocks et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Free Tubulin Modulates Mitochondrial Membrane Potential in Cancer Cells
- (2010) E. N. Maldonado et al. CANCER RESEARCH
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
- (2010) W. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
- (2009) C Stengel et al. BRITISH JOURNAL OF CANCER
- Proline Oxidase Functions as a Mitochondrial Tumor Suppressor in Human Cancers
- (2009) Y. Liu et al. CANCER RESEARCH
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- TTI-237: A Novel Microtubule-Active Compound with In vivo Antitumor Activity
- (2008) C. F. Beyer et al. CANCER RESEARCH
- Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53
- (2008) Julien Giustiniani et al. CELLULAR SIGNALLING
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells
- (2008) L. Shen et al. MOLECULAR CANCER THERAPEUTICS
- p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
- (2008) Keiko Kawauchi et al. NATURE CELL BIOLOGY
- Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy
- (2008) Saroj P. Mathupala et al. SEMINARS IN CANCER BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started